[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vitiligo---evaluation-of-methotrexate-iontophoresis-and-topical-methotrexate-gel-as-localized-treatment-approache\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vitiligo---evaluation-of-methotrexate-iontophoresis-and-topical-methotrexate-gel-as-localized-treatment-approache":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100609002","methotrexate-iontophoresis-versus-methotrexate-1-gel-on-depigmentation-in-vitiligo-patients-100609002",false,"NCT07208890","Methotrexate Iontophoresis Versus Methotrexate 1% Gel on Depigmentation in Vitiligo Patients","Inclusion Criteria:Clinically diagnosed vitiligo confirmed by a dermatologist.\n\nStable vitiligo for at least 6 months (no new lesions or progression).\n\nAge between 18 and 60 years.\n\nBoth male and female patients.\n\nPresence of localized or segmental vitiligo suitable for topical treatment.\n\nWillingness to avoid other vitiligo treatments (e.g., phototherapy, corticosteroids) during the study period.\n\nAble and willing to provide written informed consent and comply with study procedures -\n\nExclusion Criteria:History of systemic or topical methotrexate use within the past 3 months.\n\nUnstable or rapidly progressive vitiligo during the last 6 months.\n\nPresence of other autoimmune or dermatologic disorders that could interfere with study evaluation (e.g., psoriasis, eczema, lupus).\n\nKnown hypersensitivity or allergy to methotrexate or any gel\u002Fiontophoresis components.\n\nHepatic, renal, or hematologic impairment (abnormal liver function or renal profile).\n\nPregnant or breastfeeding women, or those planning pregnancy during the study period.\n\nUse of phototherapy, corticosteroids, or immunosuppressive therapy within the last 3 months.\n\nMetal implants or pacemakers, which may contraindicate iontophoresis\n\n\\-",true,"ALL","18 Years","40 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","Vitiligo is a common autoimmune depigmenting disorder characterized by selective destruction of melanocytes. Methotrexate (MTX) has shown potential in stabilizing disease activity and promoting repigmentation; however, systemic administration may cause hepatotoxicity. This pilot study aims to compare the efficacy and safety of methotrexate iontophoresis versus topical methotrexate 1% gel in patients with vitiligo. Thirty patients will be randomly assigned into two equal groups: Group A will receive methotrexate iontophoresis (5-10 mA, 15 min\u002Fsession) for 8 weeks, while Group B will apply methotrexate 1% gel twice daily for 8 weeks. Outcomes will be assessed using the Vitiligo Area and Severity Index (VASI) and the Vitiligo Impact Scale-22 (VIS-22), with liver function monitored monthly",[27],"Vitiligo - Evaluation of Methotrexate Iontophoresis and Topical Methotrexate Gel as Localized Treatment Approache","NOT_YET_RECRUITING","2025-09-27",{"date":31,"type":32},"2025-10-06","ACTUAL",{"date":34,"type":21},"2025-11-10",{"date":36,"type":21},"2026-03-10",{"name":38,"class":39},"Pharos University in Alexandria","OTHER"]